Recently, the pan-RAF inhibitor tovorafenib (DAY101), provided encouraging response data in pediatric and young adult pretreated patients with recurrent or progressive low-grade glioma or advanced solid tumors harboring a known activating BRAF alteration (NCT04775485). This evidence concerns the gene BRAF and glioma.